A grandma of 11 and a New Jersey man have joined the growing chorus of users of the wildly popular weight-loss drugs Ozempic ...

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...